Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Notes underwriting agrmnt
Histogen Inc. (CNAT) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/11/2023 8-K Quarterly results
Docs: "Histogen Reports First Quarter 2023 Results and Provides Business Update Received FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Signed Exclusive Intellectual Property License Agreement with Johns Hopkins University Steven J. Mento Ph.D. Appointed President and CEO SAN DIEGO, May 11, 2023 – Histogen Inc. , a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today reported financial results for the first quarter ended March 31, 2023, and provided an updat..."
03/09/2023 8-K Quarterly results
Docs: "Histogen Reports Year-End 2022 Results and Provides Business Update Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, March 9, 2023 – Histogen Inc. , a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today reported financial results for the year ended December 31, 2022, and provided an update on its pipeline and other corporate developments. “Our team is very excited about the new direction of the company. We remain focused on the development of emricasan as a potential treatment for acute bacterial skin and skin structure infections , includ..."
11/10/2022 8-K Quarterly results
Docs: "Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update SAN DIEGO, Nov. 10, 2022 – Histogen Inc. , a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2022 and provided an update on its clinical pipeline and other corporate developments. “We remain focused on the feasibility of developing emricasan as a potential treatment for bacterial skin infections including those related to methicillin resistant staphylococcus aureus and evaluating our caspase-1 inhibitors that impact the inflammasome pathway,” s..."
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
Docs: "Histogen Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023"
11/10/2021 8-K Quarterly results
Docs: "Histogen Reports Third Quarter 2021 Earnings and Provides Business Update Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee On- Going with Top-Line Data Expected in the Second Half of 2022"
03/11/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Received $2M Grant Award from DoD to support the HST-003 Trial for Cartilage Regeneration in the Knee. In September, Histogen was awarded a $2 million grant by the Peer Reviewed Orthopedic Research Program of the U.S. Department of Defense to help fund a Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee. Histogen expects to start the trial in the first quarter of 2021. The Phase 1/2 clinical trial is designed to evaluate HST-003 in combination with a microfracture procedure in 15 civilian and military patients with recent focal cartilage defects in the knee caused by injury. Patients will be enrolled at three clinical sites: OasisMD in San Diego, CA, The Steadman Clinic in Vail, CO and Walter Reed Medical Center in Bethesda, MD. In addition to safety parameters,..."
08/13/2020 8-K Quarterly results
05/01/2020 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports First Quarter 2020 Financial Results and Strategic Process Update"
03/11/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results"
08/06/2019 8-K Quarterly results
05/02/2019 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports First Quarter 2019 Financial Results and Program Updates"
03/08/2019 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates"
11/01/2018 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates"
08/01/2018 8-K Quarterly results
05/02/2018 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports First Quarter 2018 Financial Results and Program Updates"
03/07/2018 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports 2017 Financial Results and Program Updates"
11/01/2017 8-K Quarterly results
08/02/2017 8-K Quarterly results
05/04/2017 8-K Form 8-K - Current report
03/15/2017 8-K Form 8-K - Current report
11/08/2016 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports Third Quarter 2016 Financial Results and Program Updates"
08/03/2016 8-K Form 8-K - Current report
05/05/2016 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports First Quarter 2016 Financial Results and Program Updates"
03/09/2016 8-K Form 8-K - Current report
11/04/2015 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports Third Quarter 2015 Financial Results and Program Updates"
08/05/2015 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports Second Quarter 2015 Financial Results and Program Updates"
05/07/2015 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports First Quarter 2015 Financial Results and Program Updates"
03/11/2015 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports 2014 Financial Results and Program Updates"
11/12/2014 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports Third Quarter 2014 Financial Results and Program Updates"
08/13/2014 8-K Quarterly results
Docs: "Conatus Pharmaceuticals Reports Second Quarter 2014 Financial Results and Program Updates"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy